1.Bathen TF,
Geurts B,
Sitter B,
Fjøsne HE,
Lundgren S,
Buydens LM,
Gribbestad IS,
Postma G,
Giskeødegård GF.
Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery. PLoS One.
2013 Apr 17;8(4):e61578.
doi: 10.1371/journal.pone.0061578.
2.Bathen TF,
Jensen LR,
Sitter B,
Fjösne HE,
Halgunset J,
Axelson DE,
Gribbestad IS,
Lundgren S.
MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread,
grade,
and hormone status. Breast Cancer Res Treat.
2007 Aug;104(2):181-9.
3.Borgan E,
Lindholm EM,
Moestue S,
Mælandsmo GM,
Lingjærde OC,
Gribbestad IS,
Børresen-Dale AL,
Engebraaten O,
Sørlie T.
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. Mol Oncol.
2013 Feb;7(1):130-42.
4.Borgan E,
Sitter B,
Lingjærde OC,
Johnsen H,
Lundgren S,
Bathen TF,
Sørlie T,
Børresen-Dale AL,
Gribbestad IS.
Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer.
2010 Nov 16;10:628.
5.Cao MD,
Giskeødegård GF,
Bathen TF,
Sitter B,
Bofin A,
Lønning PE,
Lundgren S,
Gribbestad IS.
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer.
2012 Jan 25;12:39.
6.Cao MD,
Sitter B,
Bathen TF,
Bofin A,
Lønning PE,
Lundgren S,
Gribbestad IS.
Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed.
2012 Feb;25(2):369-78.
7.Cheng LL,
Chang IW,
Smith BL,
Gonzalez RG.
Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson.
1998 Nov;135(1):194-202.
8.Choi JS,
Baek HM,
Kim S,
Kim MJ,
Youk JH,
Moon HJ,
Kim EK,
Han KH,
Kim DH,
Kim SI,
Koo JS.
HR-MAS MR spectroscopy of breast cancer tissue obtained with core needle biopsy: correlation with prognostic factors. PLoS One.
2012;7(12):e51712.
9.Choi JS,
Baek HM,
Kim S,
Kim MJ,
Youk JH,
Moon HJ,
Kim EK,
Nam YK.
Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapy. PLoS One.
2013 Dec 19;8(12):e83866.
10.Esmaeili M,
Bathen TF,
Engebråten O,
Maelandsmo GM,
Gribbestad IS,
Moestue SA.
Quantitative 31 P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts. Magn Reson Med.
2013 Jul 22
11.Giskeødegård GF,
Grinde MT,
Sitter B,
Axelson DE,
Lundgren S,
Fjøsne HE,
Dahl S,
Gribbestad IS,
Bathen TF.
Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res.
2010 Feb 5;9(2):972-9.
12.Giskeødegård GF,
Lundgren S,
Sitter B,
Fjøsne HE,
Postma G,
Buydens LM,
Gribbestad IS,
Bathen TF.
Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers. NMR Biomed.
2012 Nov;25(11):1271-9.
13.Grinde MT,
Moestue SA,
Borgan E,
Risa Ø,
Engebraaten O,
Gribbestad IS.
13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns. NMR Biomed.
2011 Dec;24(10):1243-52.
14.Grinde MT,
Skrbo N,
Moestue SA,
Rødland EA,
Borgan E,
Kristian A,
Sitter B,
Bathen TF,
Børresen-Dale AL,
Mælandsmo GM,
Engebraaten O,
Sørlie T,
Marangoni E,
Gribbestad IS.
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.Breast Cancer Res.
2014 Jan 21;16(1):R5.
15.Jensen LR,
Huuse EM,
Bathen TF,
Goa PE,
Bofin AM,
Pedersen TB,
Lundgren S,
Gribbestad IS.
Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI,
ex vivo HR MAS,
and in vivo 1H MRS. NMR Biomed.
2010 Jan;23(1):56-65.
16.Klomp DW,
van de Bank BL,
Raaijmakers A,
Korteweg MA,
Possanzini C,
Boer VO,
van de Berg CA,
van de Bosch MA,
Luijten PR.31P MRSI and 1H MRS at 7 T: initial results in human breast cancer. NMR Biomed.
2011 Dec;24(10):1337-42.
17.Li M,
Song Y,
Cho N,
Chang JM,
Koo HR,
Yi A,
Kim H,
Park S,
Moon WK.An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS One.
2011;6(10):e25563.
18.Maria RM,
Moraes TB,
Magon CJ,
Venâncio T,
Altei WF,
Andricopulo AD,
Colnago LA.
Processing of high resolution magic angle spinning spectra of breast cancer cells by the filter diagonalization method. Analyst.
2012 Oct 7;137(19):4546-51.
19.Morvan D.
Functional metabolomics uncovers metabolic alterations associated to severe oxidative stress in MCF7 breast cancer cells exposed to ascididemin. Mar Drugs.
2013 Oct 11;11(10):3846-60.
20.Moestue SA,
Borgan E,
Huuse EM,
Lindholm EM,
Sitter B,
Børresen-Dale AL,
Engebraaten O,
Maelandsmo GM,
Gribbestad IS.
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.
BMC Cancer.
2010 Aug 17;10:433.
21.Moestue SA,
Dam CG,
Gorad SS,
Kristian A,
Bofin A,
Mælandsmo GM,
Engebråten O,
Gribbestad IS,
Bjørkøy G.
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res.
2013 Feb 28;15(1):R16.
22.Pacholczyk B,
Fabiańska A,
Kusińska R,
Potemski P,
Kordek R,
Jankowski S.
Analysis of cancer tissues by means of spectroscopic methods.Contemp Oncol (Pozn).
2012;16(4):290-4.
23.Righi V,
Andronesi OC,
Mintzopoulos D,
Black PM,
Tzika AA.
High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors.Int J Oncol.
2010 Feb;36(2):301-6.
24.Sitter B,
Bathen TF,
Singstad TE,
Fjøsne HE,
Lundgren S,
Halgunset J,
Gribbestad IS.Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed.
2010 May;23(4):424-31.
25.Sitter B,
Lundgren S,
Bathen TF,
Halgunset J,
Fjosne HE,
Gribbestad IS.Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.NMR Biomed.
2006 Feb;19(1):30-40.
26.Sitter B,
Sonnewald U,
Spraul M,
Fjösne HE,
Gribbestad IS.High-resolution magic angle spinning MRS of breast cancer tissue.NMR Biomed.
2002 Aug;15(5):327-37.
27.Thomas MA,
Lipnick S,
Velan SS,
Liu X,
Banakar S,
Binesh N,
Ramadan S,
Ambrosio A,
Raylman RR,
Sayre J,
DeBruhl N,
Bassett L.
Investigation of breast cancer using two-dimensional MRS. NMR Biomed.
2009 Jan;22(1):77-91.
28.Vermeer LS,
Fruhwirth GO,
Pandya P,
Ng T,
Mason AJ.
NMR metabolomics of MTLn3E breast cancer cells identifies a role for CXCR4 in lipid and choline regulation. J Proteome Res.
2012 May 4;11(5):2996-3003.
TESIS DOCTORALES
1.Siver Andreas Moestue defended his PhD thesis on 20.
January 2012.The thesis title was "Molecular and functional characterization of breast cancer through a combination of MR imaging,
transciptomics and metabolomics."
2.
Maria Dung Cao defended her PhD thesis on 14.
March 2012.
The thesis title is "MR metabolic characterization of locally advanced breast cancer - treatment effects and prognosis”